Abstract: Isolated MHC-derived human peptides, particularly an isolated MHC-derived human peptide including a SDVGE-X-R (SEQ ID NO: 13) 7 amino acids motif that is selected from: NQEESVRFDSDVGEFR (Hpep 1-SEQ ID NO:1), NREEYARFDSDVGEFR (Hpep2-SEQ ID NO:2), NREEYVRFDSDVGEYR (Hpep4-SEQ ID NO:4) and any peptide with a length of 16 amino acids including the SDVGE-X-R (SEQ ID NO: 13) motif and having an amino acid sequence with at least 80, 85, 86, 87, 88, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity with SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 4. Also, the use of these peptides in methods for inducing an immune tolerance, for preventing or reducing transplant rejection or graft versus host disease (GVHD), and in methods for isolating and expanding a population of CD8+CD45RClow Tregs or for expanding a population of CD8+CD45RClow Tregs and stimulating its immunosuppressive activity.

Abstract: Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the 5 CFTR Cl— channel and affects several organs, but the most severe consequences are observed in the lung. The inventors have now instigated the combination of Orkambi® and ANO1 TSB (SEQ ID NO:1) and show that said combination increases mucociliary clearance and chloride channel activity. Thus the combination represents an alternative treatment for CF subjects.

Abstract: The present invention relates to a vector for use in the treatment of amyotrophic lateral sclerosis associated, or not associated, with fronto temporal dementia and related motoneuron disorders, which vector comprises cholesterol 24-hydroxylase encoding nucleic acid.

Abstract: The treatment of cancer using platinum-based compounds includes certain drawbacks such as biocompatibility, loading efficacy, leakage of drugs during storage and in the bloodstream, more particularly due to the nature of the nanocarriers for platinum delivery. A nanosystem that allows improving platinum-based drug in vivo performance, kinetics and efficacy. In particular, nanoparticles useful as drug delivery system, these nanoparticles being formed from at least: (a) platinum-based drug, (b) poly-L-arginine, and (c) hyaluronic acid. Particularly, these nanoparticles have been tested in terms of entrapment efficiency and also carried out in vitro experiments in 2D cell culture (viability studies on B6KPC3, A549 and HT-29 cells) and 3D cell model (spheroids made of HTC-116) and in vivo experiments (by injecting intravenously to mice the nanoparticles or comparative oxaliplatin solution) to prove their efficiency.

Abstract: An in-ear stimulation system including a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject. Each of the first device and the second device includes: at least one in-ear active electrode configured to receive a bio-signal and at least one in-ear reference electrode configured to receive a bio-signal; at least one stimulation device configured for emitting at least one electrical or sensory stimulus; and an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.

Abstract: The present invention relates to the identification of a novel allele of the RHD gene associated with a weak D phenotype and the kits and methods for detecting this allele.

Abstract: A method for detecting movements of a plurality of points (P) of a surface (21), comprising a measuring step during which an incident ultrasonic wave is emitted into the air towards the surface and an ultrasonic wave reflected into the air by the surface (21) is detected. During the measuring step, each measuring point is illuminated by the incident ultrasonic wave at a multiplicity of angles of incidence, and the reflected ultrasonic wave is detected by a network of receiving transducers (3) comprising a plurality of ultrasonic receiving transducers (3a). The movements of the surface are determined at a measuring point by determining a delay and/or a phase shift between two beam-forming signals for said measuring point.

Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

Abstract: Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).

Abstract: The invention concerns a detecting apparatus (12) comprising:—at least two sensors (24, 26, 28), with at least one sensor (24) being an ultrasound transducer adapted to produce ultrasound waves, and—a positioning device (16) defining several compartments (22), each compartment (22) being adapted to hold a sensor (24, 26, 28) and each compartment (22) being located at predetermined location, the positioning device (16) comprising a holder adapted to be fixed on the skull of a subject, the positioning device (16) being adapted to be maintained on the head of the subject using the holder.

Abstract: Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.

Abstract: The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.

Abstract: A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10?4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.

Abstract: A method for determining a flow rate and/or a concentration of particles of a fluid flowing in a chamber, which includes the steps of: producing an ultrasound beam of a given frequency with a first transducer such that all fluid components traveling through an intersection region between the ultrasound beam and the chamber are insonated by the first transducer; receiving Doppler-shifted ultrasound signals generated by the fluid components in the insonated region of the chamber with a second transducer; acquiring the ultrasound signals received by the second transducer during an acquisition time; obtaining a Doppler Power Spectrum of the acquired ultrasound signals; and determining the flow rate and/or the concentration of particles of the fluid by adjustment between, on the one hand, the obtained Doppler Power Spectrum and, on the other hand, a model of the Doppler Power Spectrum.

Abstract: The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.

Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.

Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.

Abstract: A device for acclimatising at altitude comprising a breathing mask defining a confined air space when it is placed on the face of a user. The mask comprising a suction valve to let the surrounding air enter inside the confined space when breathing in; an expiration valve to let air exit with a determined resistance, so as to create an overpressurisation of air in the confined space, when breathing out; and a sensor to establish information about the pressure of the confined space behind. The acclimatisation device in addition comprises a unit for processing the pressure information configured to establish a breathing characteristic of the user and compare it to at least one target value, in view of recommending to them an adjustment of the breathing mode thereof. A method for functioning this device is also provided.

Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Abstract: Methods and systems are provided for decoding movement intentions using functional ultrasound (fUS) imaging of the brain. In one example, decoding movement intentions include determining a memory phase of a cognitive state of the brain, the memory phase between a gaze fixation phase and movement execution phase, and determining one or more movement intentions including one or more of intended effector (e.g., hand, eye) and intended direction (e.g., right, left) according to a machine learning algorithm trained to classify one or more movement intentions simultaneously.